Compare RMT & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | ETON |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.5M | 683.7M |
| IPO Year | N/A | 2018 |
| Metric | RMT | ETON |
|---|---|---|
| Price | $12.78 | $24.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 135.9K | ★ 471.3K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | $8.63 | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $7.62 | $13.09 |
| 52 Week High | $13.01 | $27.29 |
| Indicator | RMT | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 56.50 |
| Support Level | $10.24 | $16.38 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.27 | 1.20 |
| MACD | 0.16 | -0.12 |
| Stochastic Oscillator | 86.26 | 48.01 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.